DPP-IV inhibitor may affect spermatogenesis

Abstract A 39-year-old physician was diagnosed retrograde ejaculation due to diabetes and treated with amoxapine. This treatment was effective; he could ejaculate. He began receiving DPP-IV inhibitor (Sitagliptin 50 mg, daily), in lieu of insulin injection. Unusual effect on semen quality was occurr...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2011-08, Vol.93 (2), p.e74-e75
Main Authors: Hibi, Hatsuki, Ohori, Tadashi, Yamada, Yoshiaki
Format: Article
Language:English
Subjects:
Adult
Amoxapine - therapeutic use
Azoospermia
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
DPP-IV inhibitor
Ejaculation - drug effects
Endocrinology & Metabolism
Humans
Male
Neurotransmitter Uptake Inhibitors - therapeutic use
Pyrazines - adverse effects
Pyrazines - therapeutic use
Retrograde ejaculation
Semen Analysis
Sitagliptin Phosphate
Spermatogenesis - drug effects
Triazoles - adverse effects
Triazoles - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A 39-year-old physician was diagnosed retrograde ejaculation due to diabetes and treated with amoxapine. This treatment was effective; he could ejaculate. He began receiving DPP-IV inhibitor (Sitagliptin 50 mg, daily), in lieu of insulin injection. Unusual effect on semen quality was occurred following the administration of the drug.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2011.04.022